par Klijn, J G;Beex, Louk;Mauriac, L;van Zijl, J A;Veyret, C;Wildiers, J;Jassem, J.;Piccart-Gebhart, Martine
;Burghouts, J;Becquart, Dominique;Seynaeve, Carine;Becquart, D;Duchateau, L
Référence Journal of the National Cancer Institute, 92, 11, page (903-911)
Publication Publié, 2000-06

Référence Journal of the National Cancer Institute, 92, 11, page (903-911)
Publication Publié, 2000-06
Article révisé par les pairs
Titre: |
|
Auteur: | Klijn, J G; Beex, Louk; Mauriac, L; van Zijl, J A; Veyret, C; Wildiers, J; Jassem, J.; Piccart-Gebhart, Martine; Burghouts, J; Becquart, Dominique; Seynaeve, Carine; Becquart, D; Duchateau, L |
Informations sur la publication: | Journal of the National Cancer Institute, 92, 11, page (903-911) |
Statut de publication: | Publié, 2000-06 |
Sujet CREF: | Sciences bio-médicales et agricoles |
MeSH keywords: | Adult |
Antineoplastic Agents, Hormonal -- therapeutic use | |
Breast Neoplasms -- blood | |
Breast Neoplasms -- drug therapy | |
Buserelin -- therapeutic use | |
Disease-Free Survival | |
Drug Therapy, Combination | |
Estradiol -- blood | |
Estrogen Receptor Modulators -- therapeutic use | |
Female | |
Gonadotropin-Releasing Hormone -- blood | |
Humans | |
Menstrual Cycle -- drug effects | |
Middle Aged | |
Premenopause | |
Prognosis | |
Prospective Studies | |
Risk Factors | |
Selective Estrogen Receptor Modulators -- therapeutic use | |
Survival Analysis | |
Tamoxifen -- therapeutic use | |
Time Factors | |
Treatment Outcome | |
Note générale: | Clinical Trial |
Journal Article | |
Multicenter Study | |
Randomized Controlled Trial | |
Langue: | Anglais |
Identificateurs: | urn:issn:0027-8874 |
info:pmid/10841825 |